Multicenter, Phase I, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Ascending Doses of Subcutaneous MSB0010841 (Anti-IL17A/F Nanobody) in Male and Female Subjects With Moderate to Severe Psoriasis

Trial Profile

Multicenter, Phase I, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Ascending Doses of Subcutaneous MSB0010841 (Anti-IL17A/F Nanobody) in Male and Female Subjects With Moderate to Severe Psoriasis

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs ALX 0761 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Merck KGaA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Mar 2017 Results published in an Ablynx Media Release.
    • 06 Mar 2017 According to an Ablynx media release, Merck KGaA presented results from this study at the 75th Annual Meeting of the American Academy of Dermatology Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top